z-logo
open-access-imgOpen Access
Impact of the 8th Edition of the AJCC-TNM Staging System on Estimated Cancer-Specific Survival in Patients Aged 45–54 Years at Diagnosis with Differentiated Thyroid Carcinoma: A Single Center Report
Author(s) -
Riccardo Maggiore,
F. Perticone,
Gilberto Mari,
Riccardo Pasquali,
Emanuele Bosi,
Marina Scavini,
Roberto Lanzi,
Riccardo Rosati
Publication year - 2021
Publication title -
international journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.875
H-Index - 60
eISSN - 1687-8345
pISSN - 1687-8337
DOI - 10.1155/2021/8820364
Subject(s) - medicine , thyroid cancer , cancer , oncology , single center , thyroid carcinoma , center (category theory) , general surgery , thyroid , chemistry , crystallography
Background The 8 th edition of the American Joint Committee on Cancer (AJCC) staging system changed the age cutoff for risk stratification of differentiated thyroid carcinoma (DTC), downgrading patients between 45 and 54 years to stage I or II. The aim of our study was to assess cancer-specific survival (CSS) in patients aged 45–54 years, in order to document the prognostic capability of the last edition of the staging system.Methods We retrospectively reviewed the medical records of 172 patients that from January 1 st , 2005, to May 31 st , 2017, were diagnosed at our institution with DTC when aged 45–54 years. We restaged patients according to the 8 th edition of the staging system and estimated CSS.Results 101 out of 172 patients (58.7%) were reallocated to a lower stage. Of the 101 downstaged patients, 88 (88.9%) showed a high or intermediate American Thyroid Association (ATA) risk of recurrence. We recorded no cancer-specific deaths.Conclusions Risk of cancer-specific mortality in patients aged 45–54 years with DTC is low, supporting the prognostic capability of the 8 th edition of the staging system. However, we recommend to consider carefully the significant proportion of patients at intermediate or high risk of recurrence in this group of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom